Wednesday 21 September

General Assembly

S1.1a Gaps in the guidelines for the clinical management of candidemia

Arnaldo Lopes Colombo, Brazil

S1.1b Should we continue to use conventional doses of candins for all ICU patients?

Subhash Todi, India

S1.1c Intra-abdominal candidiasis: best clinical management and strategies to monitor response to therapy

Prakash Shastri, India

S1.1d Risk Factors Associated with Oropharyngeal Candidiasis in COVID-19 Patients: A Case Control Study

Mohammadreza Salehi, Iran

Q&A with all speakers

S1.2a 'Veterinary relevant and zoonotic fungal groups'

Amir Seyedmousavi, USA

S1.2b Penicilliosis: an emerging concern in dogs?

Jacques Guillot, France

S1.2c Diagnosis of fungal infections in animals: combining the old and the new to maximize results

Andrea Peano, Italy

S1.2d Evolutionary trends of Trichophyton mentagrophytes/T. interdigitale Species Complex originating from animals

Chao Tang, Netherlands

S1.3a Genetics and Genomics of Malassezia species

Giuseppe Ianiri, Italy

S1.3b Chromosomal stability and speciation in the Malassezia Clade

Kaustuv Sanyal, India

S1.3c Diversity and hybridization in Malassezia furfur

Bart Theelen, Netherlands

S1.3d TBD

Q&A with all speakers

S1.4a Paradigm shift in the epidemiology of invasive fungal infections during COVID-19 pandemics

Atul Patel, India

S1.4b Challenges in diagnosing & management of invasive fungal infections during pandemic

Methee Chayakulkeeree, Thailand

S1.4c Antifungal stewardship & infection control

Pratibha Kale, India

S1.4d Cryptococcus qPCR assays: the future for routine mycology labs and clinical trials dealing cryptococcosis

Alexandre Alanio, France

Q&A with all speakers

S1.5a Epidemiology of myotic keratitis in developing countries

Phillip Thomas, India

S1.5b Epidemiology of mycotic keratitis in West Africa

Harish Gugnani, India

S1.5c Proteomics approach in the understanding of fungal keratitis

Lalitha Prajna, India

S1.5d Spectrum of Aetiological agents of Mycotic keratitis: A 11 year review

Phillip Thomas, India

Q&A with all speakers

S2.1a Mucormycosis in Developing/Asian country

Atul Patel, India

S2.1b Update in pathogenesis and diagnosis of mucormycosis

Ashraf Ibrahim, USA

S2.1c Global guideline in management

Oliver Cornely, Germany

S2.1d

TBD

Q&A with all speakers

S2.2a African histoplasmosis

Rita Oladele, Nigeria

S2.2b Challenges in Latin America

Beatriz Gomez, Colombia

S2.2c Talaromycosis in HIV-negative Patients: Challenges and Countermeasures

Cunwei Cao, China

S2.2d Evaluation of new tools for the diagnosis of histoplasmosis

Aude Sturny Leclere, France

Q&A with all speakers

S2.3a Lateral Flow Device Tests for Diagnosis of Invasive Aspergillosis: What is their role in 2021?

Katrien Lagrou, Belgium

S2.3b How can Cytokines be used for Diagnosis and Treatment Monitoring of Invasive Mold Infections?

Juergen Prattes, Austria

S2.3c High Resolution Digital DNA Melting: a breakthrough in diagnosing IMI?

Tyler Goshia, USA

S2.3 Mixed biofilm of Aspergillus fumigatus and Stenotrophomonas maltophilia: microscopic visualization of galactosaminogalactan and galactomannan polysaccharides in the extracellular matrix

Françoise Botterel, France

Q&A with all speakers

S2.4a Pythiosis: an emerging disease in Hong Kong

Vanessa Barrs, Hong Kong

S2.4b Population biology of hedgehog fungus Trichophyton eninacei

Vit Hubka, Czech Republic

S2.4c Metagenomic analysis of histoplasmosis in dogs

Gregory Jouvion, France

S2.4d

TBD

S2.5a title: Magnsiomyces spp.

Axel Hamprecht, Germany

S2.5b Trichosporon spp.

João Nobrega de Almeida, Brazil

S2.5c Exophiala spp.

Joerg Steinmann, Germany

S2.5d Exploring multidrug resistance, fitness compensation and collateral sensitivity in Candida auris: fight fire with fire?

Hans Carolus, Belgium

Q&A with all speakers

S3.1a Update in mycetoma control

Ahmed Hassan Fahal, Sudan

S3.1b Chromoblastomycosis elimination S3.1b Chromoblastomycosis elimination

Daniel Wagner, Brazil

S3.1c Why sporotrichosis and Paracoccidioidomycosis should be considered neglected tropical disease?

Flavio Queiroz-Telles, Brazil

S3.1d High histoplasmosis incidence in kidney transplant recipients in Santa Fe city, Argentina

Guillermo Garcia Effron, Argentina

Q&A with all speakers

For more information about the speakers and panellist member please read more

S3.3a Lessons from the clinic: neutrophil heterogeneity in response to Candida

Michael Mansour, USA

S3.3b role of type i interferons in the host defense against pathogenic fungi

Jatin Vyas, USA

S3.3c Alveolar Macrophage mediated host resistance against Aspergillus fumigatus

Joshua Obar, UK

S3.3d Influenza- versus COVID-19-associated pulmonary aspergillosis: profiling lower respiratory tract epithelial and myeloid innate immunity in patient samples

Simon Feys, Belgium

Q&A with all speakers

S3.4a The repurposing approach identifies pitavastatin (calcium) making fluconazole fungicidal by inhibiting ergosterol synthesis

Wanqian Li, China

S3.4b Lactoferrin, a natural source of peptides that potentiate the antifungal activity of amphotericin B

Dee Carter, Australia

S3.4c A pipeline towards the identification of novel antifungal compounds derived from the microbial dark matter

Giel Vanreppelen, Belgium

S3.4d The Role of NLRP3 Inflammasome in Host Defense during Talaromyces marneffei Infection

Sha Lu, China

S3.4e Unraveling the role of DOG genes in a novel alternative pathway of glycerol biosynthesis in Candida albicans and its influence on virulence

Chinmayee Awasthy, Belgium

S3.5a Fungal contamination in sand and water of sea, lakes and river beaches: risk factor for fungal human disease

Esther Segal, Israel

S3.5b Environment as source of fungal infections: new tools and new concepts

Jean-Pierre Gangneux, France

S3.5c Animals and soil as source of fungal contamination and exposure acting as risk factor for human fungal infection

Mihai Mares, Romania

S3.5d Identification of fungicidal activity of otilonium bromide by the repurposing approach

Cheng Zhen, China

Q&A with all speakers